The effect of lowering salt intake on ambulatory blood pressure to reduce cardiovascular risk in chronic kidney disease (LowSALT CKD study): protocol of a randomized trial

BMC Nephrology

Katrina L Campbell²  Rachael E Hale¹  David W Johnson²  Michael Stowasser²  Nicole M Isbel¹  Carmel M Hawley¹  Judith D Bauer²  Emma J McMahon² 

[1] Princess Alexandra Hospital, 199 Ipswich Road, Woolloongabba, Brisbane, QLD, 4102, Australia;University of Queensland, Brisbane, 4072, Australia

关键词: Taste disturbance;    Patient compliance;    Clinical trial;    Arterial stiffness;    Cardiovascular disease;    Blood pressure;    Chronic kidney disease;    Dietary sodium;   

Others  :  1083074
DOI  :  10.1186/1471-2369-13-137

 received in 2012-10-04, accepted in 2012-10-16,  发布年份 2012

【 摘 要 】

Background

Despite evidence implicating dietary sodium in the pathogenesis of cardiovascular disease (CVD) in chronic kidney disease (CKD), quality intervention trials in CKD patients are lacking. This study aims to investigate the effect of reducing sodium intake on blood pressure, risk factors for progression of CKD and other cardiovascular risk factors in CKD.

Methods/design

The LowSALT CKD study is a six week randomized-crossover trial assessing the effect of a moderate (180 mmol/day) compared with a low (60 mmol/day) sodium intake on cardiovascular risk factors and risk factors for kidney function decline in mild-moderate CKD (stage III-IV). The primary outcome of interest is 24-hour ambulatory blood pressure, with secondary outcomes including arterial stiffness (pulse wave velocity), proteinuria and fluid status. The randomized crossover trial (Phase 1) is supported by an ancillary trial (Phase 2) of longitudinal-observational design to assess the longer term effectiveness of sodium restriction. Phase 2 will continue measurement of outcomes as per Phase 1, with the addition of patient-centered outcomes, such as dietary adherence to sodium restriction (degree of adherence and barriers/enablers), quality of life and taste assessment.

Discussion

The LowSALT CKD study is an investigator-initiated study specifically designed to assess the proof-of-concept and efficacy of sodium restriction in patients with established CKD. Phase 2 will assess the longer term effectiveness of sodium restriction in the same participants, enhancing the translation of Phase 1 results into practice. This trial will provide much-needed insight into sodium restriction as a treatment option to reduce risk of CVD and CKD progression in CKD patients.

Trial registration

Universal Trial Number: U1111-1125-2149. Australian New Zealand Clinical Trials Registry Number: ACTRN12611001097932

【 授权许可】

   
2012 McMahon et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Go AS, et al.: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004, 351(13):1296-1305.
• [2]Agrawal V, et al.: Cardiovascular implications of proteinuria: an indicator of chronic kidney disease. Nat Rev Cardiol 2009, 6(4):301-311.
• [3]Essig M, et al.: Cardiovascular remodelling and extracellular fluid excess in early stages of chronic kidney disease. Nephrol Dial Transplant 2008, 23(1):239-248.
• [4]Sacks FM, et al.: Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001, 344(1):3-10.
• [5]Ritz E, et al.: Salt–a potential 'uremic toxin'? Blood Purif 2006, 24(1):63-66.
• [6]Vaneckova I, et al.: Effects of sodium restriction and cyclooxygenase-2 inhibition on the course of hypertension, proteinuria and cardiac hypertrophy in Ren-2 transgenic rats. Physiol Res 2005, 54(1):17-24.
• [7]Verhave JC, et al.: Sodium intake affects urinary albumin excretion especially in overweight subjects. J Intern Med 2004, 256(4):324-330.
• [8]Anavekar NS, et al.: Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria. Kidney Int Suppl 2004, 92:S50-S55.
• [9]Borch-Johnsen K, Kreiner S: Proteinuria: value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus. Br Med J (Clin Res Ed) 1987, 294(6588):1651-1654.
• [10]Jurgens G, Graudal NA: Effects of low sodium diet versus high sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterols, and triglyceride. Cochrane Database Syst Rev 2004, 11:CD004022.
• [11]He FJ, MacGregor GA: Effect of longer-term modest salt reduction on blood pressure. Cochrane Database Syst Rev 2004, 2004(3):CD004937.
• [12]Graudal NA, Galloe AM, Garred P: Effects of sodium restriction on blood pressure, renin, aldosterone, catecholamines, cholesterols, and triglyceride: a meta-analysis. JAMA 1998, 279(17):1383-1391.
• [13]Midgley JP, et al.: Effect of reduced dietary sodium on blood pressure: a meta-analysis of randomized controlled trials. JAMA 1996, 275(20):1590-1597.
• [14]Hooper L, et al.: Systematic review of long term effects of advice to reduce dietary salt in adults. BMJ 2002, 325(7365):628.
• [15]Kimura G, Dohi Y, Fukuda M: Salt sensitivity and circadian rhythm of blood pressure: the keys to connect CKD with cardiovascular events. Hypertens Res 2010, 33(6):515-520.
• [16]Koomans HA, et al.: Salt sensitivity of blood pressure in chronic renal failure. Evidence for renal control of body fluid distribution in man. Hypertension 1982, 4(2):190-197.
• [17]Coresh J, et al.: Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003, 41:1-12.
• [18]Vogt L, et al.: Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol 2008, 19(5):999-1007.
• [19]Aybal A, et al.: Daily sodium intake in chronic kidney disease patients under nephrology clinic follow-up: an observational study with 24-hour urine sodium measurement. NDT Plus 2009, 2(suppl 2):ii219.
• [20]De Nicola L, et al.: Global approach to cardiovascular risk in chronic kidney disease: Reality and opportunities for intervention. Kidney Int 2006, 69(3):538-545.
• [21]Krikken JA, Laverman GD, Navis G: Benefits of dietary sodium restriction in the management of chronic kidney disease. Curr Opin Nephrol Hypertens 2009, 18(6):531-538.
• [22]Ash S, et al.: Evidence based practice guidelines for the nutritional management of chronic kidney disease. Nutr Diet 2006, 63(s2):S33-S45.
• [23]Fouque D, et al.: EBPG guideline on nutrition. Nephrol Dial Transplant 2007, 22(Suppl 2):ii45-ii87.
• [24]European Guidelines for the Nutritional Care of Adult Renal Patients. 2002. http://www.eesc.europa.eu/self-and-coregulation/documents/codes/private/086-private-act.pdf webcite.
• [25]Voss D: Nutrition and growth in kidney disease: Sodium in pre-dialysis patients. CARI guidelines; 2005. http://www.cari.org.au/CKD_nutrition_list_published/Sodium_in_pre_dialysis.pdf webcite.
• [26]Levin A, et al.: Guidelines for the management of chronic kidney disease. Cmaj 2008, 179(11):1154-62.
• [27]Ramdeen G, et al.: Estimates of interdialytic sodium and water intake based on the balance principle: differences between nondiabetic and diabetic subjects on hemodialysis. ASAIO J 1998, 44(6):812-7.
• [28]Bellizzi V, et al.: Very low protein diet supplemented with ketoanalogs improves blood pressure control in chronic kidney disease. Kidney Int 2007, 71(3):245-51.
• [29]U.S. Department of Agriculture and U.S. Department of Health and Human Services: Dietary Guidelines for Americans, 2010. 7th edition. Washington, DC: U.S: Government Printing Office; 2010.
• [30]NEMO Renal Group: Low Salt Diet. http://www.health.qld.gov.au/nutrition/resources/renal_lowsalt.pdf webcite
• [31]Heart Failure Society of America: Module 2: How to follow a low salt diet. Educational Modules on Heart Failure 2002 [cited 2011 11th April]. 2012. http://www.hfsa.org/heart_failure_education_modules.asp webcite
• [32]Koomans HA, et al.: Sodium balance in renal failure. A comparison of patients with normal subjects under extremes of sodium intake. Hypertension 1985, 7(5):714-21.
• [33]O'Brien E, et al.: Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement. J Hypertens 2005, 23(4):697-701.
• [34]Kanno A, et al.: Usefulness of assessing masked and white-coat hypertension by ambulatory blood pressure monitoring for determining prevalent risk of chronic kidney disease: the Ohasama study. Hypertens Res 2010, 33(11):1192-8.
• [35]Bangash F, Agarwal R: Masked hypertension and white-coat hypertension in chronic kidney disease: a meta-analysis. Clin J Am Soc Nephrol 2009, 4(3):656-64.
• [36]Cohen SD, et al.: Pain, sleep disturbance, and quality of life in patients with chronic kidney disease. Clin J Am Soc Nephrol 2007, 2(5):919-25.
• [37]Chen SC, et al.: Comparison of ankle-brachial index and brachial-ankle pulse wave velocity between patients with chronic kidney disease and hemodialysis [Abstract]. Am J Nephrol 2009, 29(5):374-80.
• [38]Pimenta E, et al.: Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension 2009, 54(3):475-481.
• [39]Laurent S, et al.: Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006, 27(21):2588-605.
• [40]Wilkinson IB, et al.: Reproducibility of pulse wave velocity and augmentation index measured by pulse wave analysis. J Hypertens 1998, 16(12 Pt 2):2079-84.
• [41]SphymoCor CMV Research Applications Manual: AtCor Medical Pty. Ltd.: Sydney; 2010.
• [42]Agrawal V, et al.: Cardiovascular Implications of Proteinuria: An Indicator of Chronic Kidney Disease: Measurement of Proteinuria. Medscape Education; http://www.medscape.org/viewarticle/590102_2 webcite
• [43]Fresenius Medical Care: Body Composition Monitor. [cited 2011 19/01]. 2011. http://www.bcm-fresenius.com/index.html webcite
• [44]Wabel P, et al.: Accuracy of bioimpedance spectroscopy (BIS) to detect fluid status changes is hemodialysis patients. http://www.bcm-fresenius.com/mediafiles/Pre_Post_Poster_EDTA_2007.pdf webcite.
• [45]Moissl UM, et al.: Body fluid volume determination via body composition spectroscopy in health and disease. Physiol Meas 2006, 27(9):921-33.
• [46]Body Composition Monitor. 2010. http://www.bcm-fresenius.com/index.html webcite
• [47]Thomson WM, et al.: The Xerostomia Inventory: a multi-item approach to measuring dry mouth. Community Dent Health 1999, 16(1):12-7.
• [48]Thomson WM: Measuring change in dry-mouth symptoms over time using the Xerostomia Inventory. Gerodontology 2007, 24(1):30-5.
• [49]Thomson WM, Williams SM: Further testing of the xerostomia inventory. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000, 89(1):46-50.
• [50]World Health Organization: Adherence to long-term therapies: evidence for action. World Health Organisation; 2003. http://www.who.int/chp/knowledge/publications/adherence_report/en/ webcite
• [51]Elliot P, Brown I: Sodium intakes around the world: background document prepared for the forum and technical meeting on reducing salt intake in populations. 2006. http://www.who.int/dietphysicalactivity/Elliot-brown-2007.pdf webcite
• [52]Charlton KE, et al.: Development and validation of a short questionnaire to assess sodium intake. Public Health Nutr 2007, 11(1):83-94.
• [53]Ogura M, et al.: Estimation of salt intake from spot urine samples in patients with chronic kidney disease. BMC Nephrol 2012, 13(1):36. BioMed Central Full Text
• [54]Kang SS, et al.: Use of mean spot urine sodium concentrations to estimate daily sodium intake in patients with chronic kidney disease. Nutrition 2012, 28(3):256-61.
• [55]Burke BS: The Dietary History as a Tool in Research. J Am Diet Assoc 1947, 23:1041-1046.
• [56]Martin G: The interviewer-administered, open-ended diet history method for assessing usual dietary intakes in clinical research: relative and criterion validation studies, in Department of biomedical science. Wollongong: University of Wollongong; 2004:303.
• [57]Jerusalem M, Schwarzer R: Generalized Self-Efficacy scale. In Measures in health psychology: A user’s portfolio. Causal and control beliefs. Edited by Johnston M, Weinman SWJ. Windsor, UK: NFER-NELSON; 1995:35-37.
• [58]Wallston BS, et al.: Development and validation of the health locus of control (HLC) scale. J Consult Clin Psychol 1976, 44(4):580-5.
• [59]Welch JL, et al.: Benefits of and barriers to dietary sodium adherence. West J Nurs Res 2006, 28(2):162-80.
• [60]Brekke HK, et al.: Attitudes and barriers to dietary advice aimed at reducing risk of type 2 diabetes in first-degree relatives of patients with type 2 diabetes. J Hum Nutr Diet 2004, 17(6):513-21.
• [61]Yensen R: Influence of salt deficiency on taste sensitivity in human subjects. Nature 1958, 181(4621):1472-4.
• [62]International Organization for Standardization: Sensory analysis--methodology--method of investigating sensitivity of taste: ISO 3972:2011. 1991. http://www.iso.org/iso/home/store/catalogue_ics/catalogue_detail_ics.htm?csnumber=50110 webcite
• [63]Soni RK, Weisbord SD, Unruh ML: Health-related quality of life outcomes in chronic kidney disease. Curr Opin Nephrol Hypertens 2010, 19(2):153-9.
• [64]Todd AS, et al.: Dietary salt loading impairs arterial vascular reactivity. Am J Clin Nutr 2010, 91(3):557-64.
• [65]LP S: STATA Data Analysis and Statistical Software. 2012 [cited 2012 September 26]. 2012. http://www.stata.com/ webcite
• [66]Agarwal R, Andersen MJ: Prognostic importance of ambulatory blood pressure recordings in patients with chronic kidney disease. Kidney Int 2006, 69(7):1175-80.
• [67]Haydar AA, et al.: Coronary artery calcification and aortic pulse wave velocity in chronic kidney disease patients. Kidney Int 2004, 65(5):1790-4.
• [68]Geleijnse JM, Kok FJ, Grobbee DE: Blood pressure response to changes in sodium and potassium intake: a metaregression analysis of randomised trials. J Hum Hypertens 2003, 17(7):471-80.
• [69]Brinkworth GD, et al.: Reductions in blood pressure following energy restriction for weight loss do not rebound after re-establishment of energy balance in overweight and obese subjects. Clin Exp Hypertens 2008, 30(5):385-96.